Oxford University (UK) DPhil Researcher and RegMedNet contributor, David Pettitt, invites you to share your thoughts on the factors affecting the commercialization of CAR-T therapies.
1Department of Paediatrics, Oxford University, Level 2, Children’s Hospital, John Radcliffe
Headington, Oxford, OX3 9DU, [email protected]
Dear Sir or Madam
Re: Factors Affecting the Commercialization of Cell Based Therapies
I would like to invite you to participate in a survey to assess the factors affecting the commercialization of novel therapeutics – specifically Chimeric Antigen Receptor Therapies (CAR-T).
A number of novel therapeutics are seeking to enter the clinical environment with the hope of curing what were once considered untreatable medical and/or surgical conditions. Such therapeutics are considerably different to conventional therapeutic treatment modalities, and consequently their journey to the marketplace or clinic (“commercialization”) can be complex.
In order to better delineate the commercialization process and identify factors critical to the translational pathway, we have created a brief questionnaire that incorporates a number of pertinent challenges faced by both academic and commercial entities, spanning clinical trials, regulation, manufacturing and reimbursement. It is hoped that we can successfully identify strategies to overcome the key barriers to commercialization and help expedite important treatments to the clinic.
For this reason, we ask you to complete this survey, which will take approximately 5-10 minutes. This will involve answering a series of questions relating to the aforementioned topic areas. Further details can be found in our Participant Information Sheet (PIS).
Please do not hesitate to contact us if you require further information.
Dr David Pettitt